Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Pearls & Myths: Experts Offer Advice & Dispel Myths

Thomas R. Collins  |  Issue: March 2020  |  February 25, 2020

Myth: Cyclophosphamide is more powerful than rituximab for treating GPA.

Pearl: “Methotrexate is a crummy treatment for vasculitis. The same goes for azathioprine and MMF [mycophenolate mofetil],” Dr. Stone said. “We have much better drugs now—and safer drugs. These old [treatments] that don’t work very well should be put out to pasture.”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Pearl: In IgG4-related disease, hypocomplementemia implies renal involvement. “We don’t fully understand why that is the case,” Dr. Stone said, “but it really correlates well with renal disease.”

Myth: Weight loss occurs in patients with IgG4-related disease because of overwhelming systemic inflammation. “That’s not why the weight drops off these patients,” Dr. Stone said. “It drops off these patients because they have pancreatic disease—exocrine pancreatic failure.”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

More Pearls

During the session, Sterling West, MD, professor of medicine at the University of Colorado School of Medicine, offered additional advice.

Sterling West, MD

His first rule for every case is to look for symptom causes other than a connective tissue disease. “First, ask yourself, could these symptoms be due to an adverse drug effect? Could it be due to an infection, cancer or a clot? There are some other things, but these four are particularly important, because all of them are treated differently than increased immunosuppression,” he said.

Consider sleep apnea and abuse in fibromyalgia. “You’re going to see people who have particularly severe fibromyalgia. And one of the things that has impressed us is the number of people who have sleep apnea as the cause,” Dr. West said. “We ask them, do they snore? … The other element we see is a history of sexual or physical abuse, particularly in childhood or teenage years.”

With gout, consider energy drinks. “Rule out energy drinks [as a cause], particularly for younger individuals that come in with gout,” he said. “Energy drinks have a lot of fructose in them. Fructose is broken down into ATP [adenosine triphosphate]—that’s what gives you your energy—and ATP is broken down into uric acid.”

Dr. West noted seronegative rheumatoid arthritis (RA) candidates may have calcium pyrophosphate dihydrate crystal deposition disease (CPPD) or pseudogout. “They may never have had an attack that sounds like pseudogout,” he said.

He advised, “Don’t make the diagnosis of ANA [antiphospholipid antibody] negative lupus. It’s very, very rare.”

The index finger could hold a clue to myositis in interstitial lung disease patients. A myositis panel may be indicated in these patients. Dr. West said, “Look at the radial side of their index finger—that’s where you’ll see mechanic’s hands. It may be all over their hands. But if it’s subtle, it’ll always be on the radial side of their index finger.”

Page: 1 2 3 | Single Page
Share: 

Filed under:CareerCareer DevelopmentMeeting ReportsProfessional Topics Tagged with:2019 ACR/ARP Annual Meeting

Related Articles

    Two Inflammatory Conditions—Polymyalgia Rheumatica and Giant Cell Arteritis—Share Clinical Connection

    March 1, 2013

    Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) have common clinical and epidemiologic links, but they need not occur synchronously

    Updates on Giant Cell Arteritis

    March 19, 2018

    SAN DIEGO—Recent research tells us more about giant cell arteritis (GCA) to help rheumatologists more accurately diagnose and effectively treat patients with this type of vasculitis. On Nov. 6 at the ACR/ARHP Annual Meeting, three experts explored the latest findings on GCA pathogenesis, diagnostic approaches, imaging modalities and growing treatment options. GCA: What’s Really Happening?…

    Case Report: Giant Cell Arteritis-Related Stroke

    September 10, 2023

    Thromboembolic events are major contributors to the morbidity and mortality of patients with giant cell arteritis (GCA), but little is known about how GCA may increase the risk of ischemic strokes. GCA-related stroke is described as an ischemic cerebral infarct occurring within three to four weeks of GCA diagnosis and treatment. It occurs in 3–7%…

    Autoantibodies in Autoimmune Myopathy

    Autoantibodies in Autoimmune Myopathy

    September 18, 2017

    In recent years, scientists and clinicians have learned a great deal about autoantibodies occurring in idiopathic inflammatory myopathies (IIMs). These new discoveries have reshaped our understanding of distinct clinical pheno­types in IIMs. Scientists continue to learn more about how these auto­antibodies shape pathophysiology, diagnosis, disease monitoring, prognosis and optimum treatment. Moving forward, these autoantibodies will…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences